Juhl C O, Jensen L S, Steiniche T, Moussa E
Institute of Experimental Clinical Research, University of Aarhus, Denmark.
Dig Dis Sci. 1994 Feb;39(2):393-401. doi: 10.1007/BF02090214.
Human epidermal growth factor (EGF), a naturally occurring protein, has been implicated in the protection of gastrointestinal mucosal integrity. The efficacy of EGF in the prevention of sclerotherapy-induced esophageal lesions was investigated in 18 minipigs with surgically induced portal hypertension. The animals underwent five weekly sessions of sclerotherapy with polidocanol 2% and were concomitantly treated with either placebo or EGF administered either paravenously or subcutaneously. EGF significantly (P < 0.05) reduced esophageal ulcerations, stricture formations, and mucosal histological damage associated with sclerotherapy. The drug was well-tolerated with no overt toxicity. These results suggest a potentially important clinical value of EGF as an adjunctive treatment with the sclerotherapy.
人表皮生长因子（EGF）是一种天然存在的蛋白质，它与保护胃肠道黏膜完整性有关。在18只通过手术诱导门静脉高压的小型猪中，研究了EGF预防硬化治疗引起的食管病变的疗效。这些动物每周接受5次用2%聚多卡醇进行的硬化治疗，并同时接受安慰剂或通过静脉旁注射或皮下注射给予的EGF治疗。EGF显著（P<0.05）减少了与硬化治疗相关的食管溃疡、狭窄形成和黏膜组织学损伤。该药物耐受性良好，无明显毒性。这些结果表明EGF作为硬化治疗的辅助治疗具有潜在的重要临床价值。
